Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $116.8 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Shares Outstanding (Weighted Average) rose 10.65% year-over-year to $116.8 million, compared with a TTM value of $116.8 million through Mar 2024, up 10.65%, and an annual FY2023 reading of $106.3 million, up 2.81% over the prior year.
  • Shares Outstanding (Weighted Average) was $116.8 million for Q1 2024 at Catalyst Pharmaceuticals, up from $106.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $116.8 million in Q1 2024 and bottomed at $102.8 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $104.8 million, with a median of $103.5 million recorded in 2020.
  • The sharpest move saw Shares Outstanding (Weighted Average) fell 0.99% in 2022, then increased 10.65% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $103.5 million in 2020, then decreased by 0.13% to $103.4 million in 2021, then decreased by 0.0% to $103.4 million in 2022, then increased by 2.81% to $106.3 million in 2023, then increased by 9.9% to $116.8 million in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CPRX at $116.8 million in Q1 2024, $106.3 million in Q4 2023, and $106.1 million in Q3 2023.